Vesicular stomatitis virus as an oncolytic vector

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Recent data has shown that viruses such as vesicular stomatitis virus (VSV), a relatively non-pathogenic, negative-stranded RNA virus, can preferentially replicate in malignant cells and less so in normal cells. VSV appears able to carry out this function in transformed cells since these hosts exhibit the hallmarks of flawed host defense, probably involving the interferon system, which is essential for preventing virus replication. The simple genetic constitution of VSV, lack of any known transforming, integrating or reassortment properties, extensive knowledge relating to its interaction with the immune system and the ability to genetically manipulate this agent affords an ideal opportunity to exploit the oncolytic and gene targeting potential of this innocuous virus. Thus, aside from preferentially targeting malignant cells VSV recombinants could be generated that could increase a tumor's susceptibility to chemotherapeutic agents and/ or importantly, the host immune response. Collectively, our data and others demonstrate that VSV as well as other RNA viruses could provide a promising and exciting approach to cancer therapy.

Original languageEnglish
Pages (from-to)516-527
Number of pages12
JournalViral Immunology
Volume17
Issue number4
StatePublished - Dec 1 2004

Fingerprint

Oncolytic Viruses
Vesicular Stomatitis
Viruses
RNA Viruses
Gene Targeting
Constitution and Bylaws
Virus Replication
Interferons
Immune System
Neoplasms

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Vesicular stomatitis virus as an oncolytic vector. / Barber, Glen N.

In: Viral Immunology, Vol. 17, No. 4, 01.12.2004, p. 516-527.

Research output: Contribution to journalArticle

@article{57cec425de524bdaa50b2705a357ce0d,
title = "Vesicular stomatitis virus as an oncolytic vector",
abstract = "Recent data has shown that viruses such as vesicular stomatitis virus (VSV), a relatively non-pathogenic, negative-stranded RNA virus, can preferentially replicate in malignant cells and less so in normal cells. VSV appears able to carry out this function in transformed cells since these hosts exhibit the hallmarks of flawed host defense, probably involving the interferon system, which is essential for preventing virus replication. The simple genetic constitution of VSV, lack of any known transforming, integrating or reassortment properties, extensive knowledge relating to its interaction with the immune system and the ability to genetically manipulate this agent affords an ideal opportunity to exploit the oncolytic and gene targeting potential of this innocuous virus. Thus, aside from preferentially targeting malignant cells VSV recombinants could be generated that could increase a tumor's susceptibility to chemotherapeutic agents and/ or importantly, the host immune response. Collectively, our data and others demonstrate that VSV as well as other RNA viruses could provide a promising and exciting approach to cancer therapy.",
author = "Barber, {Glen N}",
year = "2004",
month = "12",
day = "1",
language = "English",
volume = "17",
pages = "516--527",
journal = "Viral Immunology",
issn = "0882-8245",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Vesicular stomatitis virus as an oncolytic vector

AU - Barber, Glen N

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Recent data has shown that viruses such as vesicular stomatitis virus (VSV), a relatively non-pathogenic, negative-stranded RNA virus, can preferentially replicate in malignant cells and less so in normal cells. VSV appears able to carry out this function in transformed cells since these hosts exhibit the hallmarks of flawed host defense, probably involving the interferon system, which is essential for preventing virus replication. The simple genetic constitution of VSV, lack of any known transforming, integrating or reassortment properties, extensive knowledge relating to its interaction with the immune system and the ability to genetically manipulate this agent affords an ideal opportunity to exploit the oncolytic and gene targeting potential of this innocuous virus. Thus, aside from preferentially targeting malignant cells VSV recombinants could be generated that could increase a tumor's susceptibility to chemotherapeutic agents and/ or importantly, the host immune response. Collectively, our data and others demonstrate that VSV as well as other RNA viruses could provide a promising and exciting approach to cancer therapy.

AB - Recent data has shown that viruses such as vesicular stomatitis virus (VSV), a relatively non-pathogenic, negative-stranded RNA virus, can preferentially replicate in malignant cells and less so in normal cells. VSV appears able to carry out this function in transformed cells since these hosts exhibit the hallmarks of flawed host defense, probably involving the interferon system, which is essential for preventing virus replication. The simple genetic constitution of VSV, lack of any known transforming, integrating or reassortment properties, extensive knowledge relating to its interaction with the immune system and the ability to genetically manipulate this agent affords an ideal opportunity to exploit the oncolytic and gene targeting potential of this innocuous virus. Thus, aside from preferentially targeting malignant cells VSV recombinants could be generated that could increase a tumor's susceptibility to chemotherapeutic agents and/ or importantly, the host immune response. Collectively, our data and others demonstrate that VSV as well as other RNA viruses could provide a promising and exciting approach to cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=11144224896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144224896&partnerID=8YFLogxK

M3 - Article

C2 - 15671748

AN - SCOPUS:11144224896

VL - 17

SP - 516

EP - 527

JO - Viral Immunology

JF - Viral Immunology

SN - 0882-8245

IS - 4

ER -